Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study.

@article{Bhansali2014EfficacyAS,
  title={Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study.},
  author={Anil Bhansali and Premkumar Asokumar and Rama Walia and Shobhit Bhansali and Vivek Gupta and Ashish Jain and Naresh Sachdeva and Rati Ram Sharma and Neelam Marwaha and N Khandelwal},
  journal={Cell transplantation},
  year={2014},
  volume={23 9},
  pages={
          1075-85
        }
}
There is a growing interest in cell-based therapies in T2DM as β-cell failure is progressive and inexorable with the advancing duration of disease. This prospective, randomized, single-blinded placebo-controlled study evaluates the efficacy and safety of autologous bone marrow-derived stem cell transplantation (ABMSCT) in T2DM. Twenty-one patients with triple oral antidiabetic drug failure and requiring insulin ≥0.4 IU per kg per day with HbA1c <7.5% were randomly assigned to an intervention (n… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Mesenchymal stem cell therapy in type 2 diabetes mellitus

  • Diabetology & Metabolic Syndrome
  • 2017
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Myths, reality and future of mesenchymal stem cell therapy

VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED